Skip to main content
    E

    Eton Pharmaceuticals Inc (ETON)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $63.88
    -0.05 (-0.08%)

    Market Cap: $1.84B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Eton Pharmaceuticals Inc (ETON) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Eton Pharmaceuticals (ETON) trades at 36.7x trailing earnings and 13.0x sales. Its P/S of 13.0x is above its 5-year median of 6.2x. Its forward P/E is 20.8x. The median P/E across 10 similar companies is 10.5x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 76.4% higher over the next year. Its free cash flow yield is 2.1%.

    MultipleValue
    P/E (trailing)36.7x
    Forward P/E20.8x
    Price to sales13.0x
    Price to book21.1x
    EV/EBITDA38.8x
    Price to FCF47.9x
    EV/FCF47.1x
    PEGN/A
    FCF yield2.1%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S13.0x6.2xN/A
    P/B21.1x8.7xN/A
    Medians of month-end values through Oct 2026: 48 to 57 months (5-year).

    Valuation History

    Over the 5 of the 8 year ends shown that have a P/S, its P/S ranged from 3.4x in 2022 to 132.9x in 2019.

    Year endPriceP/EP/SP/B
    2025$16.91241.6x5.7x17.4x
    2024$13.32N/A8.8x14.3x
    2023$4.38N/AN/A7.3x
    2022$2.82N/A3.4x5.5x
    2021$4.29N/A4.9x6.3x
    2020$8.13N/AN/A12.4x
    2019$7.20N/A132.9x12.2x
    2018$6.12N/AN/A2.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ETON

    What is ETON's forward P/E ratio?

    Eton Pharmaceuticals has a forward P/E ratio of 20.8x.

    Is ETON stock overvalued?

    GNG's valuation label for ETON is Overvalued. Its P/E of 36.7x compares with a median of 10.5x across 10 similar companies.

    What is ETON's price to sales ratio?

    Eton Pharmaceuticals has a price to sales ratio of 13.0x.